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Abstract 
 
The intermolecular addition of 1,3-dicarbonyl equivalents to endoperoxides in the presence of an organocatalyst yields trans-fused 
butyrolactones in high yield and enantioselectivities. This methodology expands the synthetic utility of endoperoxides and further underlines 
their potential as sources of oxygen functionality for natural and non-natural product target synthesis. 
The oxidation of dienes to yield endoperoxides represents a selective and green chemical method for introducing oxygen functionality within a 
substrate.
1 
However, conversion of these endoperoxide products into useful asymmetric building blocks
1c,2 
for natural and non-natural product 
target synthesis, without the use of toxic transition metals, has yet to be fully exploited. For example, Taylor and co-workers in 2002 reported 
the conversion of endoperoxides (1) into useful butyrolactones (2) via an intermediary cis-γ-hydroxy-enone (3) (Scheme 1); however, they 
were only able to achieve this in an enantioselective fashion using a Co(II) catalyst and no asymmetric examples of bicyclic endoperoxides 
were included in their study,
2g
 presumably due to the reactivity of bicyclic endoperoxides with Co(II) salts which traditionally delivers the bis-
epoxide products.
3
 In 2006, Toste and co-workers successfully desymmetrised bicyclic endoperoxides (4) using an organocatalytic Kornblum-
De La Mare rearrangement;
4
 however, the synthetic use of these highly enantio-enriched hydroxyenone products (5) has been limited.
5
 
In a project aimed at investigating the anti-inflammatory activity of trans-fused xanthanolide natural product analogues,
6
 we recently required 
access to enantioenriched trans-fused butyrolactones (7) which we envisaged could be obtained from endoperoxides (6) (Scheme 1). While 
enantioselective routes toward cis-fused butyrolactones exist
6c-i
 general synthetic routes toward trans-fused butyrolactones are less common; 
e.g. in Shishido’s first asymmetric synthesis of the anti-inflammatory natural product xanthatin,
6j
 they had to convert a key cis-lactone 
precursor
6k
 into the trans-lactone using a 3-step procedure which included a Mitsunobu inversion of the crucial hydroxyl group. 
Scheme 1. Planned route toward trans-fused butyrolactones. 
 
 
Key to this approach is the trapping of a cyclic hydroxyenone, a result of the based catalysed rearrangement of endoperoxides, by a 1,3-
dicarbonyl equivalent which we envisaged would occur via an intermolecular 1,4-conjugate addition pathway.
2g
 Furthermore, since hydroxy 
enones such as 5 can be obtained via an organocatalysed Kornblum-De La Mare
4,7
 rearrangement of endoperoxides this approach would 
represent an asymmetric protocol for generating complex trans-fused butyrolactone scaffolds from endoperoxides, which in turn can be 
obtained from simple 
1
O2 oxidation of dienes. 
After initial optimisation studies
9
 we found treatment of endoperoxide 4
8
 in THF
9
 in the presence of 10 mol% of catalyst 8a for a 16h period 
followed by addition diethylsodiomalonate gave the desired lactone (-)-9a in an isolated yield of 76% and ee of 92% (Scheme 1 and Table 1; 
entry 1).
 10,11
 While the rearrangement of 4 with catalyst 8b with subsequent addition of diethylsodiomalonate gave lactone (+)-9a in a yield of 
78% and ee of 94% (entry 2).  
Scheme 2. Lactone optimisation. 
 With optimal conditions for lactone formation determined we then looked at the scope of this sequence using other 1,3-dicarbonyls and 
endoperoxides in the presence of both catalysts 8a and 8b (Scheme 2 and Table 1). Undertaking the reaction with dimethylsodiomalonate 
and using catalyst 8a gave lactone (-)-9b in a comparable isolated yield and ee (entry 3). The use of ethyl sodioacetoacetate failed to deliver 
the butyrolactone but instead only yielded the alkoxy Michael addition product 10 as an inseparable mixture of diastereoisomers (entry 4); 
however, the addition of ethyl sodio benzoyl acetate gave the lactone (-)-9d using catalyst 8a in an isolated yield of 82% and an ee of 94% 
(entry 5). The endoperoxide 11, obtained in 87% yield from cycloheptadiene,
12
 was also exposed to the optimised reaction conditions with 
catalyst 8a delivering (-)-13 in 82% yield and ee of 78%, while the antipode (+)-13 was obtained in an ee of 76% and a comparable isolated 
yield using catalyst 8b (entries 6 and 7, respectively). When the OTBS protected seven membered endoperoxide 12, derived from 
commercially available tropone,
13
 was treated with catalyst 8a under the optimised conditions the lactone (-)-14 was isolated in a good yield of 
74% and an excellent ee of 94%, while catalyst 8b gave the antipode (+)-14 in 70% yield and an ee of 92% (entries 8 and 9, respectively). 
Table 1. Asymmetric butyrolactone formation and scope.
a,b
 
Entry 
Endo- 
peroxide 
R Product 
Yield 
[%]
c
 
ee
d
 
1 4 CO2Et (-)-9a 76 92 
2
e
 4 CO2Et (+)-9a 78 94 
3 4 CO2Me (-)-9b 76 92 
4
f
 4 C(O)Me - - - 
5 4 C(O)Ph (-)-9d 82 94 
6 11 CO2Et 
 
82 78 
7
e
 11 CO2Et (+)-13 82 76 
8 12 CO2Et 
 
74 94 
9
e
 12 CO2Et (+)-14 70 92 
10 1 CO2Et 
 
44 10 
a
See the general experimental procedure. 
b
10 mol% of catalyst 8a used unless otherwise stated. 
c
Isolated yields. 
d
Determined by chiral 
HPLC. 
e
10 mol% of catalyst 8b. 
f
10 was isolated as an inseparable mixture of diastereoisomers. 
While the absolute stereochemistry of this later lactone can be deduced form the work of Toste,
4
 the relative stereochemistry of (±)-14 was 
definitively assigned via X-ray crystallography.
14
 Importantly, the enantioselective synthesis of lactones containing a trans-fused 5,7-ring 
system gives us access to scaffolds ideal for investigating the biologically active xanthanolide class of natural products.
6a,b
 Finally, 
endoperoxide 1 was exposed to the lactonisation conditions, but gave the known lactone (+)-2 in a disappointing ee of 10% (entry 10). 
Next we explored the installation of a methyl group at the alpha position of the trans-fused butyrolactone, as many natural product classes 
possess this substitution pattern (Scheme 3). Desymmetrisation of 4 using catalyst 8b followed by addition of diethylsodiomalonate gave the 
intermediate sodium salt 15 which upon treatment with iodomethane followed by acid mediated decarboxylation, gave the alpha methyl 
substituted lactone (+)-19 as the major diastereoisomer in 66% yield.
15
 Alternatively, the rearranged endoperoxide 4 could be treated with 
alpha-methyldiethylsodiomalonate giving lactone 17 which upon decarboxylation gave (+)-19 in a comparable chemical yield and 
diastereoselectivity. These two processes were also performed upon the seven membered endoperoxide 11 using catalyst 8a in this case, 
giving the desired alpha methyl substituted lactone (-)-20 in good chemical yield and diastereoselectivity.
16
 
Scheme 3. Direct installation of an α-methyl group. 
 
The trans-stereochemistry of the butyrolactone is installed via the mechanism shown below in Scheme 4. The hydroxyenone 23 undergoes 
conjugate addition anti to the hydroxyl group, as depicted in 25, to deliver the addition product 24. This undergoes lactonisation to deliver the 
trans-fused product 26, which can then be protonated or trapped by an appropriate electrophile therefore giving 27.
17
 
Scheme 4. Trans-fused lactone formation. 
 
Finally, in reference to accessing xanthanolide analogues, we investigated the use of the ketone contained within the fused carbocycle as a 
synthetic handle (Scheme 5). Accordingly, we were able to selectively install an exo-methylene group using the conditions of Connell and co-
workers
18
 on lactone (-)-20 giving 28. This compound proved to be unstable and was directly reduced under Luche conditions
19
 to yield the 
allylic alcohol. Subsequent exposure of this alcohol to trimethyl orthoacetate, gave the Claisen rearrangement product (-)-29 in a yield 51% 
over 3-steps from (-)-20. Therefore using this approach we have a convenient asymmetric route to trans-fused xanthanolide analogues in just 
5-steps and from readily available endoperoxides.  
Scheme 5. Synthesis of  xanthanolide analogue (-)-29. 
 
In summary, we have developed a convenient and single pot method for the synthesis of highly enantioenriched trans-fused butyrolactones 
from endoperoxides. Importantly, this process gives the desired products without the use of transitions metals and also showcases the use of 
endoperoxides as environmentally sustainable sources of oxygen functionality. The use of this methodology in the total synthesis of 
xanthanolide sesquiterpenoids and analogues for evaluation of their inflammatory activity is currently being pursued and will be reported on in 
due course. 
Experimental 
General experimental procedure for enantio-enriched lactone formation.  
To a solution of the endoperoxide (1mmol) in dry THF (5mL) was added the catalyst (0.1mmol, 8a or 8b as indicated below) and the resultant 
reaction mixture stirred at room temperature for 16h under N2. After this period a solution of the desired nucleophile (1.0mmol) [prepared in 
THF (3mL) by the addition of NaOEt or NaOMe (2.2mL, 0.5M, 1.1mmol) to the required malonate derivative (1.0mmol)] was added dropwise 
to the reaction mixture at 0˚C, and the resultant solution allowed to warm to room temperature and stirred for a further 16h under N2. The 
reaction mixture was then cooled to 0˚C and quenched by the addition of 1M HCl, after which it was partitioned between EtOAc (50mL) and 
H2O (50mL), and the aqueous layer extracted with further portions of EtOAc (2x20mL). The organic layers were then combined, washed with 
brine, dried (Na2SO4), filtered and the solvent removed in vacuo. The crude products were then purified by chromatography. Using this 
procedure then following compound were obtained: 
(-)-(3R, 3aS, 9aR)-Ethyl-2,5-dioxodecahydrocycloocta[b]furan-3-carboxylate ((-)-9a). Prepared using catalyst 8a (193 mg, 76%; Rf 0.50 in 
3:2 petroleum ether:ethyl acetate); []D
20
 = -41.2 (c 1.00, CHCl3); HRMS (ESI-orbitrap): MNa
+
, C12H16O5, found 277.1039, requires MNa
+
 
277.1052; IR (solution, CHCl3) 3032, 3019, 2942, 1784, 1734, 1708, 1209, 1159 cm
-1
; 
1
H NMR (400 MHz; CDCl3) δ 4.30 (dq, J = 2.4, 7.2 Hz, 
2H), 4.19 (ddd, J = 3.2, 8.8, 10.0 Hz, 1H), 3.41 (d, J = 12.4 Hz, 1H), 3.19 (ddt, J = 3.6, 10.0, 11.6 Hz, 1H), 2.78 – 2.68 (m, 2H), 2.43 (dd, J = 
11.6, 14.4 Hz, 1H), 2.35 (dt, J = 5.6, 12.8 Hz, 1H), 2.23 – 2.16 (m, 1H), 1.90 – 1.70 (m, 4H), 1.48 – 1.40 (m, 1H), 1.31 (t, J = 7.2 Hz, 3H); 
13
C 
NMR (100 MHz;CDCl3) δ 211.6, 169.5, 167.0, 84.1, 62.5, 53.9, 45.4, 43.9, 39.0, 31.1, 26.0, 22.1, 14.1. 3S, 3aR, 9aS)-Ethyl-2,5-
dioxodecahydrocycloocta[b]furan-3-carboxylate ((+)-9a). Prepared using catalyst 8b (196mg, 78%); []D
18
 = +45.2 (c 1.00, CHCl3).  
 (-)-(3R, 3aS, 9aR)-Methyl-2,5-dioxodecahydrocycloocta[b]furan-3-carboxylate ((-)-9b). Prepared using catalyst 8a (182mg, 76%; Rf 0.20 
in 1:1 petroleum ether/ethyl acetate; MP 70.0 – 71.5 ºC); []D
20
 = -58.0 (c 1.00, CHCl3); HRMS (ESI-orbitrap): MNa
+
, C12H16O5, found 
263.0883, requires MNa
+
 263.0895; IR (solution, CHCl3) 3033, 3019, 2946, 1785, 1743, 1708, 1216, 1209, 1159 cm
-1
; 
1
H NMR (400 MHz; 
CDCl3) δ 4.18 (ddd, J = 3.2, 8.8, 11.2 Hz, 1H), 3.86 (s, 3H), 3.42 (d, J = 12.0 Hz, 1H), 3.25 – 3.18 (m, 1H), 2.80 – 2.71 (m, 1H), 2.75 (dd, J = 
4.0, 14.8 Hz, 1H), 2.43 (dd, J = 11.6, 14.4 Hz, 1H), 2.36 (dt, J = 5.2, 12.8 Hz, 1H), 2.24 – 2.16 (m, 1H), 1.95 – 1.72 (m, 4H), 1.50 – 1.41 (m, 
1H); 
13
C NMR (100 MHz;CDCl3) δ 211.4, 169.3, 167.0, 84.1, 53.8, 53.3, 45.5, 43.9, 39.0, 31.1, 26.0, 22.1.  
(-)-(3S,3aS,9aR)-tert-Butyl 2,5-dioxodecahydrocycloocta[b]furan-3-carboxylate ((-)-9c). Prepared using catalyst 8a (191mg, 68%; Rf 0.65 
in 1:1 petroleum ether/ethyl acetate; MP 87 – 89 ºC); []D
26
 = -29.6 (c 1.00, CHCl3); HRMS (ESI-orbitrap): MNa
+
, C15H22O5, found 305.1353, 
requires MNa
+
 305.1365; IR (solution, CHCl3) 2938, 1783, 1727, 1709, 1459, 1371, 1221 cm
-1
; 
1
H NMR (400 MHz; CDCl3) δ 4.11 (ddd, J = 
3.2, 8.4, 11.6 Hz, 1H), 3.26 (d, J = 12.4 Hz, 1H), 3.12 (ddt, J = 3.6, 10.0, 14.0 Hz, 1H), 2.77 – 2.70 (m, 1H), 2.68 (dd, J = 4.0, 14.8 Hz, 1H), 
2.41 (dd, J = 12.0, 14.8 Hz, 1H), 2.33 (dt, J = 5.2, 12.8 Hz, 1H), 2.19 – 2.12 (m, 1H), 1.90 – 1.69 (m, 5H), 1.49 (s, 9H); 
13
C NMR (100 MHz; 
CDCl3) δ 211.8, 169.8, 165.7, 83.8, 83.4, 54.6, 45.5, 43.7, 39.0, 31.0, 28.0, 26.1, 22.0.  
 (-)-(3R,3aS,9aR)-3-Benzoylhexahydrocycloocta[b]furan-2,5(3H,6H)-dione ((-)-9d). Prepared using catalyst 8a (234mg, 82%; Rf 0.55 in 
1:1 petroleum ether/ethyl acetate; MP 103 - 105 ºC); []D
26
 = -122.8 (c 1.00, CHCl3); HRMS (ESI-orbitrap): MNa
+
, C17H18O4, found 309.1091, 
requires MNa
+
 309.1103; IR (solution, CHCl3) 2939, 1773, 1706, 1685, 1449, 1270 cm
-1
; 
1
H NMR (400 MHz; CDCl3) δ 8.05 – 8.03 (m, 2H), 
7.67 – 7.63 (m, 1H), 7.55 – 7.51 (m, 2H), 4.38 (d, J = 12.0 Hz, 1H), 4.27 (ddd, J = 3.6, 8.4, 10.0 Hz, 1H), 3.71 – 3.62 (m, 1H), 2.94 – 2.88 (m 
1H), 2.68 (dd, J = 4.0, 14.8 Hz, 1H), 2.39 – 2.33 (m, 1H), 2.23 – 2.19 (m, 1H), 1.96 – 1.84 (m, 4H), 1.52 – 1.48 (m, 1H); 
13
C NMR (100 MHz; 
CDCl3) δ 211.9, 191.7, 170.0, 135.8, 134.4, 129.6, 128.9, 84.1, 55.5, 45.8, 41.9, 38.6, 31.2, 26.3, 21.7.  
(-)-((3R, 3aS, 8aR)-ethyl 2,5-dioxooctahydro-2H-cyclohepta[b]furan-3-carboxylate ((-)-13). Prepared using catalyst 8a (193mg, 82%; Rf 
0.30 in 1:1 petroleum ether/ethyl acetate; MP 64.0 – 66.0 ºC); []D
19
 = -25.6 (c 1.00, CHCl3); HRMS (ESI-orbitrap): MNa
+
, C12H16O5, found 
263.1130, requires MNa
+
 263.0895; IR (solution, CHCl3) 3029, 2957, 2931, 2859, 1789, 1736, 1709, 1016 cm
-1
; 
1
H NMR (400 MHz; CDCl3) δ 
4.26 (dq, J = 1.6, 7.2 Hz, 2H), 4.09 – 4.01 (m, 1H), 3.34 (d, J = 12.4 Hz, 1H), 3.04 (ddt, J = 4.4, 10.4, 12.0 Hz, 1H), 2.78 (dd, J = 4.0, 18.0 Hz, 
1H), 2.63 (dt, J = 2.4, 13.2 Hz, 1H), 2.58 – 2.52 (m, 1H), 2.50 – 2.43 (m, 1H), 2.37 (dd, J = 12.0, 18.0 Hz, 1H), 2.11 – 2.02 (m, 1H), 1.80 – 
1.71 (m, 1H), 1.58 – 1.48 (m, 1H), 1.28 (t, J = 7.6 Hz, 3H); 
13
C NMR (100 MHz;CDCl3) δ 209.4, 169.9, 166.7, 83.6, 62.5, 53.1, 43.3, 43.1, 
42.1, 34.0, 20.7, 14.1. (+)-((3S, 3aR, 8aS)-ethyl 2,5-dioxooctahydro-2H-cyclohepta[b]furan-3-carboxylate ((+)-13). Prepared using 
catalyst 8b (188mg, 81%); []D
21
 = +29.6 (c 1.00, CHCl3).  
 (-)-(3R, 3aS, 7S, 8aR)-Ethyl 7-(tert-butyldimethylsilyloxy)-2,5-dioxooctahydro-2H-cyclohepta[b]furan-3-carboxylate ((-)-14). Using the 
general method but on a 0.40 mmol scale and prepared using catalyst 8a (107mg, 74%; Rf 0.45 in 3:1 petroleum ether/ethyl acetate; MP 
102.0 – 103.5 ºC); []D
19
 = -35.8 (c 1.00, CHCl3); HRMS (ESI-orbitrap): MNa
+
, C18H30O6Si, found 393.1696, requires MNa
+
 393.1709; IR 
(solution, CHCl3) 2957, 2931, 2858, 1789, 1736, 1708, 1260, 1016 cm
-1
; 
1
H NMR (400 MHz; CDCl3) δ 4.28 (dq, J = 2.8, 7.2 Hz, 2H), 4.10 
(ddd, J = 3.6, 10.0, 11.6 Hz, 1H), 3.93 – 3.87 (m, 1H), 3.30 (d, J = 13.2 Hz, 1H), 3.30 – 3.19 (m, 1H), 3.04 (dd, J = 11.2, 12.0 Hz, 1H), 2.87 
(dd, J = 4.8, 17.6 Hz, 1H), 2.68 – 2.64 (m, 2H), 2.29 (dd, J = 11.6, 17.6 Hz, 1H), 2.03 – 1.95 (m , 1H), 1.32 (t, J = 7.2 Hz, 3H), 0.87 (s, 9H), 
0.08 (s, 6H); 
13
C NMR (100 MHz;CDCl3) δ 205.7, 169.4, 166.4, 79.0, 66.1, 62.6, 53.3, 44.8, 43.8, 41.4, 31.0, 25.6, 18.0, 14.1, -4.9. (+)-(3S, 
3aR, 7R, 8aS)-Ethyl 7-(tert-butyldimethylsilyloxy)-2,5-dioxooctahydro-2H-cyclohepta[b]furan-3-carboxylate ((+)-14). Using the general 
method and prepared using catalyst 8b (102mg, 70%); []D
18
 = +32.6 (c 1.00, CHCl3).  
General methylation conditions. Method A: To a solution of the endoperoxide 4 or 11 (1.00mmol) in dry THF (10mL) was added the 
catalyst 8a or 8b (0.1mmol) and the resultant reaction mixture stirred at room temperature for 16h under N2. After this period a solution of 
NaCH(CO2Et)2 [1.1mmol; prepared from H2C(CO2Et)2 (193mg, 1.10mmol) and NaOEt (2.30mL, 0.5M soln., 1.15mmol) THF (5mL)] was added 
dropwise to the reaction mixture at 0˚C, and the resultant solution allowed to warm to room temperature and stirred for a further 16h under N2. 
The reaction mixture was then cooled to 0˚C and iodomethane (94μL, 1.5mmol) was added after which the reaction mixture was st irred for a 
further 16h at room temperature. A sat. solution of NH4Cl (10mL) was then added and the solution then partitioned between CH2Cl2 (50mL) 
and H2O (50mL), and the aqueous layer extracted with further portions of CH2Cl2 (2x40mL). The organic layers were then combined, washed 
with brine (50mL), dried (Na2SO4), filtered and the solvent removed in vacuo. The crude material was then dissolved in 50% AcOH (10mL) 
and refluxed overnight. After this period, the reaction was cooled, carefully basified with NaHCO3 and the aqueous layer extracted with 
dichloromethane (2x40mL). The combined organic extracts were then dried (Na2SO4), filtered, and the solvent was removed in vacuo. The 
crude product was then purified by column chromatography. Method B: To a solution of the endoperoxide 4 or 11 (1.0mmol) in dry THF 
(8mL) was added the catalyst 8a or 8b (35mg, 0.1mmol) and the resultant reaction mixture stirred at room temperature for 16h under N2. After 
this period a solution of NaCMe(CO2Et)2 [1.1mmol; prepared from HCMe(CO2Et)2 (193mg, 1.10mmol) and NaOEt (2.30mL, 0.5M soln., 
1.15mmol) THF (5mL)] was added dropwise to the reaction mixture at 0˚C, and the resultant solution allowed to warm to room temperature 
and stirred for a further 16h under N2. The reaction mixture was then cooled to 0˚C and a sat. soln. of NH4Cl (10mL) added, partitioned 
between CH2Cl2 (50mL) and H2O (50mL), and the aqueous layer extracted with further portions of CH2Cl2 (2x30mL). The organic layers were 
then combined, washed with brine (50mL), dried (Na2SO4), filtered and the solvent removed in vacuo. The crude material was then dissolved 
in 50% AcOH (10mL) and refluxed overnight. After this period, the reaction was cooled, carefully basified with NaHCO3 and the aqueous layer 
extracted with CH2Cl2 (2x40mL). The combined organic extracts were then dried (Na2SO4), filtered, and the solvent was removed in vacuo. 
The crude product was then purified by column chromatography. Using these methods the following compounds were obtained. 
(+)-(3R, 3aR, 9aS)-3-Methylhexahydrocycloocta[b]furan-2,5(3H,6H)-dione ((+)-19). Obtained as a colourless oil (Method A 130mg, 66%; 
Method B 123mg, 63%; Rf 0.18 in 3:2 petroleum ether/ ethyl acetate); []D
19
 = +26.4 (c 1.00, CHCl3); HRMS (ESI-orbitrap): MNa
+
, C11H16O3, 
found 219.0992, requires MNa
+
 219.0997; IR (solution, CHCl3) 3025, 2938, 1774, 1705, 991 cm
-1
; 
1
H NMR (400 MHz; CDCl3) δ 4.11 (dt, J = 
3.2, 9.2 Hz, 1H), 2.66 (dd, 3.6, 10.4 Hz, 1H), 2.68 – 2.61 (m, 1H), 2.45 (dd, J = 11.6, 14.0 Hz, 1H), 2.40 – 2.35 (m, 1H), 2.34 (q, J = 6.8 Hz, 
1H), 2.27 – 2.19 (m, 2H), 1.95 – 1.85 (m, 1H), 1.85 – 1.72 (m, 2H), 1.68 – 1.59 (m, 1H), 1.54 – 1.46 (m, 1H), 1.26 (d, J = 6.8 Hz, 3H); 
13
C 
NMR (100 MHz;CDCl3) δ 212.8, 177.1, 84.0, 49.0, 45.3, 42.6, 39.9, 31.4, 25.8, 22.9, 12.8. 
(-)-(3S, 3aS, 8aR)-3-Methylhexahydro-2H-cyclohepta[b]furan-2,5(3H)-dione ((-)-20). Obtained as a waxy solid (Method A (performed on a 
2mmol scale) 298mg, 79%; Method B 124mg, 68%; Rf 0.35 in 1:1 petroleum ether/ethyl acetate; MP 28 – 31˚C); []D
19
 = -92 (c 1.00, CHCl3); 
HRMS (ESI-orbitrap): MNa
+
, C10H14O3, found 205.0836, requires MNa
+
 205.0841; IR (solution, CHCl3) 3029, 3019, 2936, 1776, 1703, 1208 
cm
-1
; 
1
H NMR (400 MHz; CDCl3) δ 3.97 (ddd, J = 3.2, 9.6, 10.8 Hz, 1H), 2.78 (dd, J = 4.0, 18.0 Hz, 1H), 2.51 – 2.47 (m, 2H), 2.36 – 2.28 (m, 
1H), 2.20 – 2.15 (m, 2H), 2.12 – 2.08 (m, 1H), 2.07 – 2.03 (m, 1H), 1.72 – 1.53 (m, 2H), 1.26 (d, J = 7.6 Hz, 3H); 
13
C NMR (100 MHz;CDCl3) δ 
210.3, 177.4, 83.6, 46.2, 43.5, 43.4, 41.9, 34.3, 20.8, 12.9. 
(+)-(3aR, 9aS)-Hexahydrocycloocta[b]furan-2,5(3H,6H)-dione ((+)-21). Lactone (+)-9a (0.36g, 1.4mmol) was dissolved ethanol (15mL) and 
2M KOH (15mL) and the resultant solution stirred at room temperature for 16h. After this period the reaction mixture was carefully acidified 
with 5M HCl, extracted with CH2Cl2 (2x30mL), and the combined organic layers dried (Na2SO4), filtered and the solvent removed in vacuo. 
The crude acid was then dissolved in toluene (25mL) and refluxed for overnight. The solvent was then removed in vacuo and the crude solid 
purified by column chromatography (Rf 0.13, 3:2 petroleum ether/ethyl acetate) to yield the title compound as a colourless solid (194mg, 76%; 
MP 74 – 76 ºC); []D
19
 = +21.2 (c 1.00, CHCl3); HRMS (ESI-orbitrap): MNa
+
, C10H14O3, found 205.0836, requires MNa
+
 205.0841; IR (solution, 
CHCl3) 3011, 3027, 2942, 1780, 1705, 1016 cm
-1
; 
1
H NMR (400 MHz; CDCl3) δ 4.22 (dt, J = 3.2, 9.2 Hz, 1H), 2.77 – 2.64 (m, 4H), 2.48 (dd, J 
= 11.2, 13.6 Hz, 1H), 2.42 – 2.34 (m, 2H), 2.27 – 2.21 (m, 1H), 1.93 – 1.76 (m, 3H), 1.72 – 1.63 (m, 1H), 1.54 – 1.46 (m, 1H); 
13
C NMR (100 
MHz;CDCl3) δ 21.4, 174.4, 86.0, 46.4, 41.1, 39.7, 37.1, 31.6, 25.7, 22.8. 
 (-)-(3aS ,8aR)-hexahydro-2H-cyclohepta[b]furan-2,5(3H)-dione ((-)-22). Lactone (-)-13 (241mg, 1.00mmol) was dissolved in 50% AcOH 
(10mL) and refluxed overnight. After this period, the reaction was cooled, basified with NaHCO3 and the aqueous layer extracted with 
dichloromethane (2x30mL). The combined organic extracts were then dried (Na2SO4), filtered, and the solvent was removed in vacuo. The 
crude product were then purified by chromatography giving the title compound as a colourless solid (130mg, 78%; MP 69.0 – 70.5 ºC); []D
19
 = 
-59.6 (c 1.00, CHCl3); HRMS (ESI-orbitrap): MNa
+
, C9H12O3, found 191.0679, requires MNa
+
 191.0684; IR (solution, CHCl3) 3019, 2950, 1782, 
1704, 1211 cm
-1
; 
1
H NMR (400 MHz; CDCl3) δ 4.03 (ddd, J = 3.6, 5.2, 9.6 Hz, 1H), 2.80 (dd, J = 3.6, 18.0 Hz, 1H), 2.74 – 2.52 (m, 4H), 2.48 
(dq, J = 3.6, 12.8 Hz, 1H), 2.40 – 2.30 (m, 2H), 2.12 – 2.04 (m, 1H), 1.72 (ddt, J = 4.0, 11.2, 13.2 Hz, 1H), 1.61 – 1.50 (m, 1H); 
13
C NMR (100 
MHz;CDCl3) δ 210.3, 175.0, 85.6, 44.1, 43.3, 38.6, 35.9, 34.2, 20.8. 
(-)-Methyl 3-((3S, 3aS, 8aR)-3-methyl-2-oxo-3, 3a, 4, 7, 8, 8a-hexahydro-2H-cyclohepta[b]furan-6-yl)propanoate ((-)-29). To a mixture of 
(-)-20 (282mg, 1.55mmol) and paraformaldehyde (94mg, 3.10mmol) in dry THF (2mL) was added (
i
Pr)2NH.TFA (334mg, 1.55mmol) and TFA 
(12μL, 0.16mmol). The reaction mixture was then refluxed for 2h, after which it was cooled to room temperature and another portion of 
paraformaldehyde (94mg, 3.10mmol) added and the reaction mixture refluxed for a further 6h. After this period the reaction mixture was 
cooled, the solvent removed in vacuo and the residue dissolved in CH2Cl2 (40mL) and washed sequentially with 1M HCl (30mL), NaHCO3 
(30mL) and finally brine (30mL). The combined organic layers were then dried (Na2SO4), filtered and the solvent removed in vacuo. The crude 
oil was then purified by chromatography (Rf 0.4 in 3:1 ethyl acetate/petroleum ether) to give the desired methenylated compound as a 
colourless oil (182mg, 61%) which was used without further purification. The methenylated compound (160mg, 0.825mmol) was dissolved in 
methanol (6mL) and to this solution was added CeCl3.9H2O (308mg, 0.825mmol). The reaction mixture was cooled to 0˚C and to the stirring 
solution was added NaBH4 (102mg, 2.68mmol) in portions over 20min. After the addition the reaction mixture was then monitered by tlc until 
the disapperance of the starting material was detected. After approx. 1h the reaction was cooled once again cooled to 0˚C and carefully 
quenched with a sat. solution of NH4Cl. The reaction mixture was then transferred to a separating funnel and the aqueous extracted with ethyl 
acetate (3x20mL), and the resultant combined organic extracts dried (Na2SO4), filterred and the solvent finally removed in vacuo. The crude 
product was then immediately dissolved in trimethyl orthoacetate (1.00mL) and to this mixture was added a propionic acid (1drop). This 
solution was then heated for 16h at reflux under a N2 atmosphere. After this period the reaction mixture was cooled and the residual trimethyl 
orthoacetate removed in vacuo and the crude product purified by column chromatography (Rf 0.55 in 5:3 ethyl acetate/petroleum ether) giving 
the title compound (-)-29 as a colourless oil (172mg, 83% over 2-steps); [α]D
21
 = -50.4 (c 1.00, CHCl3); HRMS (ESI-orbitrap): MNa
+
, C14Hx20O4, 
found 275.1256, requires MNa
+
 275.1259; IR (solution, CHCl3) 2900, 1765, 1733, 1440 cm
-1
; 
1
H NMR (400 MHz; CDCl3) δ 5.77 – 5.73 (m, 
1H), 3.83 (ddd, J = 4.0, 10.0, 11.2 Hz, 1H), 3.67 (s, 3H), 2.91 – 2.86 (m, 1H), 2.79 (q, J = 6.8 Hz, 1H), 2.52 – 2.41 (m, 4H), 2.39 – 2.35 (m, 
2H), 2.24 – 2.16 (m, 1H), 2.11 – 2.01 (m, 1H), 1.81 – 1.75 (m, 1H), 1.71 – 1.60 (m, 1H), 1.31 (d, J = 6.8 Hz, 3H); 
13
C NMR (100 MHz;CDCl3) δ 
178.5, 173.2, 136.2, 130.0, 79.0, 52.7, 51.8, 38.0, 37.1, 32.8, 27.4, 26.7, 24.0, 15.7. 
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